Ustekinumab May Trigger Acute CV Events Early in Treatment Ustekinumab May Trigger Acute CV Events Early in Treatment
Initiating treatment with ustekinumab, an IL-12/23-targeting monoclonal antibody, may trigger early severe cardiovascular events in susceptible patients.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 18, 2020 Category: Dermatology Tags: Dermatology News Source Type: news

FDA Approves Stelara (ustekinumab) for Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
HORSHAM, Pa., July 30, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Stelara (ustekinumab) as a treatment... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 30, 2020 Category: Drugs & Pharmacology Source Type: news

Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic...
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, PENNSYLVANIA, June 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE.The decision is based on data from a pre-planned interim efficacy analysis. Interim safety findings were consistent with the known safety profile of STELARA, and no new safety signals were identified. Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyze the totality of...
Source: Johnson and Johnson - June 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, Pa., June 26, 2020 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Ery... Biopharmaceuticals Janssen Pharmaceutical, Johnson & Johnson, STELARA, ustekinumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 26, 2020 Category: Pharmaceuticals Source Type: news

Johnson & Johnson Reports 2020 First-Quarter Results:
New Brunswick, N.J. (April 14, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share compared to the previous rate of $3.80 per share. “With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic,” sai...
Source: Johnson and Johnson - April 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

Ustekinumab reduces costs and utilisation in US patients with Crohn's disease
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - April 1, 2020 Category: Drugs & Pharmacology Source Type: news

FDA OKs Ustekinumab (Stelara) for Moderate to Severe UC FDA OKs Ustekinumab (Stelara) for Moderate to Severe UC
Ustekinumab was more effective than placebo for inducing and maintaining remission and promoting mucosal healing in a study of adults with moderately to severely active ulcerative colitis.FDA Approvals (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - October 22, 2019 Category: Internal Medicine Tags: Gastroenterology News Alert Source Type: news

Janssen Announces FDA Approval of Stelara (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
HORSHAM, PENNSYLVANIA, October 21, 2019– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the U.S. Food and Drug Administration’s (FDA) approval of Stelara (ustekinumab) for the treatment of adult patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 21, 2019 Category: Drugs & Pharmacology Source Type: news

Janssen Announces U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative
In the Phase 3 pivotal trial, more than 40 percent of patients receiving STELARA subcutaneous (SC) injections every 8 weeks were in clinical remission at one year and not taking corticosteroidsSTELARA is the first and only approved treatment for ulcerative colitis to demonstrate improvement of the colon as measured by a novel histologic-endoscopic mucosal improvement endpoint (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 21, 2019 Category: Pharmaceuticals Source Type: news

Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions
WEDNESDAY, Sept. 25, 2019 -- In moderate-to-severe ulcerative colitis, vedolizumab is superior to adalimumab for achieving clinical remission and endoscopic improvement, but not corticosteroid-free clinical remission, and ustekinumab is superior to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 25, 2019 Category: Pharmaceuticals Source Type: news

Sarcoid-Like Ustekinumab Induced Granulomatous Reaction Sarcoid-Like Ustekinumab Induced Granulomatous Reaction
This patient presented with a rare disseminated sarcoid-like reaction while undergoing treatment with the monoclonal antibody ustekinumab for refractory psoriasis.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

ustekinumab (Stelara)
Title: ustekinumab (Stelara)Category: MedicationsCreated: 1/5/2010 12:00:00 AMLast Editorial Review: 8/5/2019 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - August 5, 2019 Category: Dermatology Source Type: news

Risankizumab vs. Ustekinumab for Plaque Psoriasis Risankizumab vs. Ustekinumab for Plaque Psoriasis
A recent head-to-head study compared risankizumab with ustekinumab for treatment of moderate-to-severe chronic plaque psoriasis. This critical assessment examines the validity of the results.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Infection Risk Lower With Certain Psoriasis Treatments
MONDAY, May 13, 2019 -- For patients with psoriasis treated with systemic medications, the risk for serious infection is reduced for new users of apremilast, etanercept, and ustekinumab versus methotrexate, according to a study published online May... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 13, 2019 Category: Pharmaceuticals Source Type: news

HLA-C*06:02 Negativity Shouldn't Bar Ustekinumab Treatment for Psoriasis HLA-C*06:02 Negativity Shouldn't Bar Ustekinumab Treatment for Psoriasis
Although being positive for the HLA-C*06:02 genotype is associated with a better response to ustekinumab therapy in patients with plaque psoriasis, those with negative findings also do well, according to Dutch researchers.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 30, 2019 Category: Pathology Tags: Dermatology News Source Type: news

Drug Survival Rates Highest for Ustekinumab for Pediatric Psoriasis
THURSDAY, March 28, 2019 -- In real-life conditions, drug survival rates are higher for ustekinumab than for adalimumab and etanercept for all treatments and types of psoriasis in children, according to a study published online March 18 in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 28, 2019 Category: Pharmaceuticals Source Type: news

Brodalumab as an Alternative to Ustekinumab in Psoriasis Brodalumab as an Alternative to Ustekinumab in Psoriasis
Is brodalumab effective in treating moderate-to-severe psoriasis in patients who do not achieve adequate response with ustekinumab?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 18, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Medical News Today: Stelara vs. Humira: What's the difference?
Stelara and Humira are two biologics that help treat immune conditions, such as psoriatic arthritis and Crohn ’s disease. In this article, we look at the similarities and differences in their effects, benefits, and risks. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 14, 2019 Category: Consumer Health News Tags: Rheumatology Source Type: news

New Phase 3 Stelara ® (Ustekinumab) Data Show Positive Results as Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - March 11, 2019 Category: Pharmaceuticals Source Type: news

J & J Raises U.S. Prices on Around Two Dozen Drugs J & J Raises U.S. Prices on Around Two Dozen Drugs
Johnson& Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara (ustekinumab), prostate cancer drug Zytiga (abiraterone) and blood thinner Xarelto (rivaroxaban), all among its top-selling products.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 14, 2019 Category: Consumer Health News Tags: Medscape Today News Source Type: news

J & J raises U.S. drug prices
Johnson& Johnson raised U.S. prices on around two dozen drugs, including psoriasis treatment, Stelara, prostate cancer drug, Zytiga, and blood thinner, Xarelto. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 11, 2019 Category: Pharmaceuticals Source Type: news

J & amp;J raises U.S. drug prices
Johnson& Johnson raised U.S. prices on around two dozen drugs, including psoriasis treatment, Stelara, prostate cancer drug, Zytiga, and blood thinner, Xarelto. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - January 11, 2019 Category: Pharmaceuticals Source Type: news

J & J raises U.S. prices on around two dozen drugs
Johnson& Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among its top-selling products. (Source: Reuters: Health)
Source: Reuters: Health - January 11, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Noninfectious Pneumonia Tied to Ustekinumab Use Noninfectious Pneumonia Tied to Ustekinumab Use
Treatment with ustekinumab (Stelara, Janssen Biotech) may be associated with noninfectious pneumonia, according to a report by the U.S. Food and Drug Administration (FDA).Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 28, 2018 Category: Intensive Care Tags: Pulmonary Medicine News Source Type: news

Two-Drug Regimen Fails to Stem Psoriasis Relapse
(MedPage Today) -- Study looks at costimulatory blockade with abatacept after stopping ustekinumab (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - December 18, 2018 Category: Primary Care Source Type: news

Minimal Disease Activity and Acceptable Symptom State in PsA Minimal Disease Activity and Acceptable Symptom State in PsA
A new study provides evidence of the safety and efficacy of ustekinumab in psoriatic arthritis in a real-world setting.Journal of Clinical Rheumatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 26, 2018 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

ACR: IL-12/23 Blocker Offers Long-Term Benefits in SLE
(MedPage Today) -- Responses were sustained out to 1 year with ustekinumab (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - October 24, 2018 Category: Rheumatology Source Type: news

New Phase 2 Data Show Stelara ® (Ustekinumab) Sustained Improvement in Disease Activity in Adults With Systemic Lupus Erythematosus Through One Year
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 23, 2018 Category: Pharmaceuticals Source Type: news

Stelara a Hit in Ulcerative Colitis
(MedPage Today) -- Clinical remission achieved with two different doses of interleukin 12/23 blocker (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 11, 2018 Category: Gastroenterology Source Type: news

J & J's Stelara Succeeds in Ulcerative Colitis Study J & J's Stelara Succeeds in Ulcerative Colitis Study
Johnson& Johnson said on Tuesday its blockbuster drug Stelara (ustekinumab) was found to be effective in treating ulcerative colitis (UC) in a late-stage trial.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 10, 2018 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

New phase 3 data show single dose of stelara ® (ustekinumab) induces clinical remission and response in adults with moderate to severe ulcerative colitis
(Source: Johnson and Johnson)
Source: Johnson and Johnson - October 10, 2018 Category: Pharmaceuticals Source Type: news

J & amp;J blockbuster find late-stage trial success in chronic bowel disease study
Stelara was previously approved for psoriasis, psoriatic arthritis and Crohn's disease (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 10, 2018 Category: Pharmaceuticals Source Type: news

J & J's Stelara succeeds in chronic bowel disease study
Johnson& Johnson said on Tuesday its blockbuster drug Stelara was found to be effective in treating a chronic bowel disease in a late-stage trial. (Source: Reuters: Health)
Source: Reuters: Health - October 9, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Pooled analyses from ultIMMa-1 and ultIMMa-2 studies showed significantly more patients treated with risankizumab were symptom-free (psoriasis symptom scale [PSS] score of 0) compared to placebo and STELARA® (ustekinumab) after 16 weeks and at one year... Biopharmaceuticals, Dermatology AbbVie, Risankizumab, psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 13, 2018 Category: Pharmaceuticals Source Type: news

Ustekinumab for Crohn's Disease: Long-term Efficacy, Safety Ustekinumab for Crohn's Disease: Long-term Efficacy, Safety
This study assessed long-term extension data of ustekinumab for Crohn's disease, demonstrating the maintenance of response and remission and continued safety through 92 weeks.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 14, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Enthesitis in PsA: A New Focus of Treatment?
(MedPage Today) -- Targeting IL-23 with ustekinumab cleared enthesitis in three-quarters of patients (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - June 23, 2018 Category: Dermatology Source Type: news

Ustekinumab: Novel Help in Vasculitis?
(MedPage Today) -- Steroid-sparing effects demonstrated in small pilot study (Source: MedPage Today Primary Care)
Source: MedPage Today Primary Care - May 24, 2018 Category: Primary Care Source Type: news

Predictors of Response to Vedolizumab and Ustekinumab in IBD Predictors of Response to Vedolizumab and Ustekinumab in IBD
What factors and patient characteristics might help predict initial and long-term response to vedolizumab and ustekinumab in inflammatory bowel disease?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 8, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Long-term Efficacy, Safety of Ustekinumab in Refractory CD Long-term Efficacy, Safety of Ustekinumab in Refractory CD
This study evaluated the long-term efficacy and safety of ustekinumab in anti-TNF refractory Crohn's disease patients.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 12, 2018 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Fecal Microbiota Profile Predicts Ustekinumab Response in Crohn's Fecal Microbiota Profile Predicts Ustekinumab Response in Crohn's
Data on patients ’ fecal microbiota can be used to predict their response to ustekinumab therapy for Crohn's disease, researchers report.Reuters Health Information (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - March 26, 2018 Category: Pathology Tags: Gastroenterology News Source Type: news

Experimental Biologic Surpasses Ustekinumab for Psoriasis Experimental Biologic Surpasses Ustekinumab for Psoriasis
A biologic under investigation for severe psoriasis has topped one of the most effective therapies on the market in head-to-head phase 3 trials.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - February 20, 2018 Category: Allergy & Immunology Tags: Dermatology News Source Type: news

Risankizumab Resolves Psoriasis in Half of Patients
(MedPage Today) -- Superior to ustekinumab for many endpoints in two RCTs (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - February 19, 2018 Category: Dermatology Source Type: news

Ustekinumab Makes Inroads in Crohn's Disease
(MedPage Today) -- Docs opt for psoriasis drug when anti-TNF agents fail (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - January 22, 2018 Category: Gastroenterology Source Type: news

Novartis new data reinforces superiority of Cosentyx(R) versus Stelara(R) in achieving skin clearance for psoriasis patients
Results from CLARITY study show Cosentyx® (secukinumab) was significantly more effective than Stelara® (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks(1) Data support findings from the CLEAR study, which found... Biopharmaceuticals Novartis, Cosentyx, secukinumab, plaque psoriasis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 16, 2018 Category: Pharmaceuticals Source Type: news

Biological Therapies and Improvements in QoL in Psoriasis Biological Therapies and Improvements in QoL in Psoriasis
This study compared the effectiveness of adalimumab, etanercept and ustekinumab on improvements in HRQoL in patients with psoriasis. What factors are associated with these improvements?The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 16, 2018 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news

Stelara ® (ustekinumab) shows positive results in treatment of systemic lupus erythematosus in phase 2 trial
(Source: Johnson and Johnson)
Source: Johnson and Johnson - November 6, 2017 Category: Pharmaceuticals Source Type: news

J & J's Stelara shows promise against lupus in study
(Reuters) - Johnson& Johnson's blockbuster psoriasis drug Stelara led to a significant reduction in disease activity in patients with systemic lupus compared with a placebo in a midstage clinical trial, according to data released on Saturday. (Source: Reuters: Health)
Source: Reuters: Health - November 5, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Risankizumab outperforms ustekinumab in psoriasis trial
The IL-23 inhibitor risankizumab was superior to ustekinumab in a phase two trial of adult patients with moderate-to-severe chronic plaque psoriasis, researchers report. (Source: Dermatology Times)
Source: Dermatology Times - October 19, 2017 Category: Dermatology Source Type: news

FDA Clears Ustekinumab (Stelara) for Plaque Psoriasis in Teens FDA Clears Ustekinumab (Stelara) for Plaque Psoriasis in Teens
For at least two thirds of patients aged 12 to 17 years who were treated with ustekinumab, cleared skin or minimal psoriasis was achieved at week 12 in a phase 3 study.FDA Approvals (Source: Medscape Med Students Headlines)
Source: Medscape Med Students Headlines - October 16, 2017 Category: Universities & Medical Training Tags: Dermatology News Alert Source Type: news